`Patent 8,633,194
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`APOTEX INC.
`Petitioner,
`
`v.
`
`UCB BIOPHARMA SPRL,
`Patent Owner.
`______________
`
`Case IPR2019-00400
`Patent 8,633,194
`______________
`
`
`PATENT OWNER’S RESPONSE TO PETITIONER’S OBJECTIONS TO
`EVIDENCE
`
`
`
`
`IPR2019-00400
`Patent 8,633,194
`
`Patent Owner UCB Biopharma Sprl (“Patent Owner”) submits the following
`
`in response to Petitioner Apotex Inc.’s (“Apotex”) Objections to Evidence (Paper
`
`23), dated and served on October 21, 2019. Patent Owner reserves all rights to
`
`respond to Petitioner’s objections to Exhibits not specifically referenced below and
`
`to respond further to Petitioner’s objections to Exhibits that are referenced below.
`
`Section 42.64(b)(1) requires that evidentiary objections “must identify the
`
`grounds for the objection with sufficient particularity to allow correction in the form
`
`of supplemental evidence.” 37 C.F.R. § 42.64(b)(1); 77 Fed. Reg. 48767 (Aug. 14,
`
`2012). Petitioner’s objections, including its objections to Exhibits 2030 and 2031
`
`under Federal Rules of Evidence 801 and/or 802, contain conclusory references to
`
`the Federal Rules of Evidence, and do not provide the required particularity.
`
`All of Patent Owner’s Exhibits were cited by Patent Owner in its Response or
`
`by Patent Owner’s declarant, Dr. Sarfaraz K. Niazi, in his supporting declaration.
`
`As explained therein, none lack relevance under Federal Rules of Evidence 402 or
`
`403. Petitioner’s relevance objections to Exhibits 2024, 2030, 2031 and paragraphs
`
`6, 71-73, 191-193, and 196-197 of the Declaration of Dr. Sarfaraz K. Niazi (Exhibit
`
`2034) mischaracterize the purpose of these Exhibits. Exhibits 2030 and 2031, and
`
`the related portions of Dr. Niazi’s declaration, demonstrate the difficulty of
`
`predicting antibacterial properties of chemical compounds, even after the priority
`
`date. Similarly, Exhibit 2024, and the related portions of Dr. Niazi’s declaration, are
`
`
`
`1
`
`
`
`IPR2019-00400
`Patent 8,633,194
`
`presented to inform that preservatives are still today generally classified into six
`
`categories. See EX2034 at ¶ 56. Petitioner’s expert, Dr. Laskar, previously agreed
`
`that these categories of preservatives were used in 2004. See EX2034 at ¶ 56;
`
`EX2010 43:2-44:1. Exhibits 2024, 2030, and 2031 were not presented as prior art.
`
`Patent Owner reserves all rights to respond to any further explanations
`
`Petitioner is allowed to provide regarding its evidentiary objections.
`
`
`Dated: November 4, 2019
`
`
`
`Respectfully submitted,
`
`FENWICK & WEST LLP
`/s/ Robert E. Counihan (electronically
`signed)
`James S. Trainor, Reg. No. 52,297
`Lead Counsel
`
`Robert E. Counihan, Reg. No. 61,382
`Back-Up Counsel
`
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600
`jtrainor@fenwick.com
`rcounihan@fenwick.com
`
`Erica R. Sutter, Reg. No. 77,450
`Back-Up Counsel
`
`FENWICK & WEST LLP
`801 California Street
`Mountain View, CA 94041
`(650) 988-8500
`
`2
`
`
`
`
`IPR2019-00400
`Patent 8,633,194
`
`
`esutter@fenwick.com
`
`Counsel for Patent Owner UCB Biopharma
`Sprl
`
`
`
`
`
`3
`
`
`
`
`CERTIFICATE OF SERVICE
`
`IPR2019-00400
`Patent 8,633,194
`
`
`Pursuant to 37 C.F.R. § 42.6(e), I hereby certify that on November 4, 2019,
`
`the foregoing document is being served by filing this document through the Patent
`
`Trial and Appeal Board End to End System, as well as by delivering a copy via
`
`electronic mail upon the following counsel of record for the Petitioner:
`
`jitty.malik@kattenlaw.com
`alissa.pacchioli@kattenlaw.com
`joe.janusz@kattenlaw.com
`lance.soderstrom@kattenlaw.com
`
`
`Date: November 4, 2019
`
`
`
`
`Respectfully submitted,
`
`
`
`
`
`/s/ Robert E. Counihan (electronically
`signed)
`Robert E. Counihan
`Reg. No. 61,382
`Phone: (212) 430-2600
`
`
`
`
`